S1PR1 and multiple sclerosis: Furthermore, the existence of next‐generation S1PR1‐targeted agents like Ozanimod (Zeposia, Celgene) and Siponimod (Mayzent), FDA‐approved drugs for the treatment of multiple sclerosis,50 suggests promising avenues for further advancements in this field.